[ad_1]
New York, July 12, 2021 (GLOBE NEWSWIRE)–Reportlinker.com announced the release of the “Global Gene Therapy Industry” report- https://www.reportlinker.com/p05817594/?utm_source=GNW
It will be 5 million in 2020, and it is expected to reach a revised scale of US$3.4 billion by 2027. It will grow at a compound annual growth rate of 19.5% during 2020-2027. The virus in one of the market segments analyzed in the report is expected to grow to the end of the analysis period, with a compound annual growth rate of 19.7%, reaching US$3 billion. After an early analysis of the business impact of the pandemic and the economic crisis it caused, the growth of the non-viral segment was re-adjusted to a revised 17.6% compound annual growth rate over the next 7 years. This segment currently accounts for 11.1% of the global gene therapy market.
The U.S. will account for more than 53.7% of the global market in 2020, while China is expected to have a compound annual growth rate of 25.1% during 2020-2027
By 2020, the US gene therapy market is estimated to be USD 521.3 million. The country currently accounts for 53.71% of the global market share. China is the world’s second largest economy, and its market size is expected to reach 107.9 million US dollars by 2027, and its compound annual growth rate by 2027 is 25.1%. Other notable geographic markets include Japan and Canada, which are expected to grow by 17.3% and 18.9% during 2020-2027, respectively. In Europe, Germany is expected to grow at a compound annual growth rate of approximately 18.6%, while other European markets (as defined in the study) will reach US$107.9 million by 2027.
Select a competitor (154 selected in total)
- Abeona Therapeutics Inc.
- Adaptimmune Therapeutics Plc
- Advantage Gene Company
- Adverum Biotechnology Company
- Akcea therapy
- Alnylam Pharmaceutical Company
- Amgen
- Anchiano Therapeutics, Inc.
- Angus
- Applied Genetic Technologies
- Audentes Therapeutics, Inc.
- Biogen
- Bluebird Bio
- Chiesi Farmaceutici SpA
- CRISPR Therapeutics AG
- Issuing medical companies
- Gilead Sciences
- Intellia Therapeutics, Inc.
- Jazz Pharmaceuticals
- Juno Therapeutics
- Merck
- Moore Medical Corporation
- Novartis Gene Therapy
- Orchard Therapy Company
- REGENXBIO company
- Sangamo Therapeutics, Inc.
- Sarepta Therapeutics, Inc.
- Sibiono GeneTech Co. Ltd.
- Spark Therapeutics, Inc.
- Unique NV
- Voyager Therapy
Read the full report: https://www.reportlinker.com/p05817594/?utm_source=GNW
1. Methodology
2. Executive Summary
1. Market overview
Influencer market insights
World market trajectory
The impact of Covid-19 and the imminent global recession
Prelude to gene therapy
Classification of gene therapy
COVID-19 causes the gene therapy market to collapse
The impact of COVID-19 on different aspects of gene therapy
Manufacturing and delivery
Research and clinical development
Commercial operations and visits
Manage derailed operations
Focus on clinical development plans
Targeting manufacturing and delivery strategies
Ensure supply
Remote work
Gene therapy will witness rapid growth after COVID-19
By vector type
Viral vectors account for a major share of the market
Adeno-associated virus vector
Lentivirus
Witness the rapid growth of non-viral vectors
The U.S. and Europe dominate the gene therapy market
Oncology is the biggest indication for gene therapy
Market outlook
World Brand
2. Focus on selected players
Recent market activity
Choose innovation
3. Market trends and driving factors
Availability of new therapies drives market growth
Choose an approved gene therapy product
Adeno-associated virus vector-leading gene platform
treatment
Lentiviral vectors are getting more and more attention
The global increase in cancer incidence spurs demand for gene therapy
Chart 1: Global cancer incidence: number of new cancer cases
Millions in 2018, 2020, 2025, 2030, 2035 and 2040
Chart 2: Number of new cancer cases and cancer-related cases worldwide
Number of deaths from cancer sites in 2018
Chart 3: Number of new cancer cases and deaths (millions)
2018 by region
Fascinating technology and level of innovation ignite gene therapy
Promising gene therapy innovations for the treatment of genetic diseases
Retinal disease
Gene therapy promotes mergers and acquisitions in the field of genome dynamics
drug
M&A rampant in gene therapy
Gene therapy deals: 2018 and 2019
Emphasize the development of a robust regulatory framework
Powerful gene therapy pipeline
Gene therapy: Phase III clinical trial
OHSU implements the first LCA10 gene therapy clinical trial
Use CRISPR
Increase funding for gene therapy research
Market issues and challenges
4. Global market perspective
Table 1: Current status and future analysis of global gene therapy
Geographical area-United States, Canada, Japan, China, Europe,
Asia Pacific and the rest of the world market-independent analysis
Annual sales from 2020 to 2027 (in thousands of U.S. dollars) and
% Compound annual growth rate
Table 2: Historical review of gene therapy world by region
Regions-United States, Canada, Japan, China, Europe, Asia Pacific and
Other markets in the world-independent analysis of annual sales
Thousands of U.S. dollars and% CAGR from 2017 to 2019
Table 3: Global 10-year gene therapy outlook
Geographic Region-Percentage breakdown of sales value
U.S., Canada, Japan, China, Europe, Asia Pacific and other regions
World markets in 2017, 2020 and 2027
Table 4: Current status and future analysis of the virus in the world
Geographical area-United States, Canada, Japan, China, Europe,
Asia Pacific and the rest of the world market-independent analysis
Annual sales from 2020 to 2027 (in thousands of U.S. dollars) and
% Compound annual growth rate
Table 5: A review of the world history of the virus by geographic area-
U.S., Canada, Japan, China, Europe, Asia Pacific and other regions
World Market-Independent analysis of annual sales in U.S. dollars
Thousand sum% from 2017 to 2019
Table 6: 10-year World Virus Outlook by Region
Region-United States, Canada,
Over the years, Japan, China, Europe, Asia Pacific and the rest of the world
2017, 2020 and 2027
Table 7: Non-viral world status and future analysis
Geographical area-United States, Canada, Japan, China, Europe,
Asia Pacific and the rest of the world market-independent analysis
Annual sales from 2020 to 2027 (in thousands of U.S. dollars) and
% Compound annual growth rate
Table 8: Non-viral World History Review by Geographic Region
Regions-United States, Canada, Japan, China, Europe, Asia Pacific and
Other markets in the world-independent analysis of annual sales
Thousands of U.S. dollars and% CAGR from 2017 to 2019
Table 9: Non-viral 10-year World Outlook by Geographic Region
Region-United States, Canada,
Over the years, Japan, China, Europe, Asia Pacific and the rest of the world
2017, 2020 and 2027
Table 10: Global Oncology Status and Future Analysis
Diseases by geographic area-United States, Canada, Japan, China,
Markets in Europe, Asia Pacific and the rest of the world-independent
Analysis of annual sales in thousands of U.S. dollars from 2020 to 2020
2027 and% CAGR
Table 11: Historical review of tumor diseases in the world
Geographical area-United States, Canada, Japan, China, Europe,
Asia Pacific and the rest of the world market-independent analysis
2017 to 2019 annual sales (in thousands of U.S. dollars) and
% Compound annual growth rate
Table 12: 10-year outlook on the world’s tumor diseases
Breakdown by Geographic Region-Percentage of Sales Value
U.S., Canada, Japan, China, Europe, Asia Pacific and other regions
The world in 2017, 2020 and 2027
Table 13: Current status and future analysis of rare diseases in the world
Geographical area-United States, Canada, Japan, China, Europe,
Asia Pacific and the rest of the world market-independent analysis
Annual sales from 2020 to 2027 (in thousands of U.S. dollars) and
% Compound annual growth rate
Table 14: World history review of rare diseases by region
Regions-United States, Canada, Japan, China, Europe, Asia Pacific and
Other markets in the world-independent analysis of annual sales
Thousands of U.S. dollars and% CAGR from 2017 to 2019
Table 15: 10-year outlook for rare diseases in the world
Geographic Region-Percentage breakdown of sales value
U.S., Canada, Japan, China, Europe, Asia Pacific and other regions
The world in 2017, 2020 and 2027
Table 16: World Current Status and Future Analysis of Neurology
Diseases by geographic area-United States, Canada, Japan, China,
Markets in Europe, Asia Pacific and the rest of the world-independent
Annual sales analysis…
The full story on Benzinga.com
[ad_2]
Source link
